EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effects of imeglimin on liver enzymes and body composition in patients with MASLD and type 2 diabetes: a pilot study

Kaede Fujita, Takanobu Iwadare, Takefumi Kimura iD, Yuma Kamijo, Taiki Okumura, Shun-Ichi Wakabayashi, Hiroyuki Kobayashi, Tomoo Yamazaki, Naoki Tanaka, Hideo Kunimoto

Diabetology International · 2026-10 · 17 (4)

DOI: 10.1007/s13340-026-00931-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetology International, online erschienen am 05.10.2026. Verfasst von Kaede Fujita und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology, Nagano Municipal Hospital, Nagano, Japan. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shinshu University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent in patients with type 2 diabetes mellitus (T2DM), yet effective pharmacological options remain limited. Imeglimin, a novel antidiabetic agent targeting mitochondrial bioenergetics, has shown potential hepatoprotective effects in preclinical studies; however, its impact on liver function and body composition in MASLD remains unclear.

Methods

This retrospective, single-center pilot study analyzed prospectively collected data from 28 patients with MASLD and T2DM who were treated with imeglimin for 6 months. Clinical and biochemical parameters were assessed at baseline and at 3 and 6 months. Body composition was evaluated using bioelectrical impedance analysis.

Results

Over 6 months, fasting blood glucose decreased from 148.5 to 131.0 mg/dL ( p = 0.015), accompanied by reductions in liver enzymes (aspartate aminotransferase: 33–26 U/L, p < 0.001; alanine aminotransferase: 28.5–23.5 U/L, p = 0.001). Body weight and body fat percentage also decreased ( p < 0.001 and p = 0.018, respectively), whereas no statistically significant changes were observed in skeletal muscle mass. No serious adverse events were reported.

Conclusion

Imeglimin therapy was associated with favorable changes in glycemic parameters, liver enzymes, and body composition in this pilot cohort, without a statistically significant reduction in skeletal muscle mass. These findings suggest a potential metabolic and hepatic effect of imeglimin and may be particularly relevant for patients with MASLD at risk of sarcopenia. Larger prospective studies with histological or validated non-invasive endpoints are warranted.

Schlagwörter

Stichwörter der Autor:innen

ImegliminMetabolic dysfunction-associated steatotic liver diseaseType 2 diabetes

Autor:innen und Institutionen

  • Department of Hepatology, Nagano Municipal Hospital, Nagano, Japan.
  • Department of Medicine, Division of Gastroenterology, Shinshu University School of Medicine, Matsumoto, Japan.
  • Consultation Center for Liver Diseases, Shinshu University Hospital, Matsumoto, Japan.
  • Institute for Biomedical Sciences, Research Cluster for Social Implementation, Matsumoto, Japan.
  • Department of Global Medical Research Promotion, Shinshu University Graduate School of Medicine, Matsumoto, Japan.
  • International Relations Office, Shinshu University School of Medicine, Matsumoto, Japan.

ORCID-Profile: Takefumi Kimura

Förderung

  • Shinshu University

Zitieren

APA

Fujita, K., Iwadare, T., Kimura, T., Kamijo, Y., Okumura, T., Wakabayashi, S. I., Kobayashi, H., Yamazaki, T., Tanaka, N., & Kunimoto, H. (2026). Effects of imeglimin on liver enzymes and body composition in patients with MASLD and type 2 diabetes: a pilot study. Diabetology International, 17(4). https://doi.org/10.1007/s13340-026-00931-4

Vancouver

Fujita K, Iwadare T, Kimura T, Kamijo Y, Okumura T, Wakabayashi SI, et al. Effects of imeglimin on liver enzymes and body composition in patients with MASLD and type 2 diabetes: a pilot study. Diabetology International. 2026;17(4). doi:10.1007/s13340-026-00931-4

BibTeX
@article{Fujita2026,
  author = {Fujita, Kaede and Iwadare, Takanobu and Kimura, Takefumi and Kamijo, Yuma and Okumura, Taiki and Wakabayashi, Shun-Ichi and Kobayashi, Hiroyuki and Yamazaki, Tomoo and Tanaka, Naoki and Kunimoto, Hideo},
  title = {Effects of imeglimin on liver enzymes and body composition in patients with MASLD and type 2 diabetes: a pilot study},
  journal = {Diabetology International},
  year = {2026},
  volume = {17},
  number = {4},
  doi = {10.1007/s13340-026-00931-4}
}
Kostenlos starten →